Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
The DOI matches its Crossref record; 416 of the 416 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. PARTICIPANTS: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. EVIDENCE: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. CONSENSUS PROCESS: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. CONCLUSIONS: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have not associated HRT in women 40-49 years with increased risk of breast cancer (161), and there is no evidence that estrogen replacement in women with premature ovarian failure relates to a higher risk of breast cancer ( 162).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [162]
Citations
Cites
Items 201–400 of 416
Manson, J. E., Rimm, E. B., Colditz, G. A., Willett, W. C., Nathan, D. M., Arky, R. A., Rosner, B., Hennekens, C. H., Speizer, F. E., & Stampfer, M. J. (1992) · Annals of Epidemiology · doi:10.1016/1047-2797(92)90011-e · Cited by 135 · cited 1×
“studies (61, 62) reported that MHT reduced the preva-”
BackgroundPharmacokinetics and Pharmacodynamics of Conjugated Equine Estrogens: Chemistry and Metabolism
Bhavnani, B. R. (1998) · Experimental Biology and Medicine · doi:10.3181/00379727-217-44199 · Cited by 135 · cited 1×
“pounds with varying estrogenic potency (160).”
Frei-Kleiner, S., Schaffner, W., Rahlfs, V. W., Bodmer, C., & Birkhäuser, M. (2004) · Maturitas · doi:10.1016/j.maturitas.2004.10.003 · Cited by 135
Mood disorders in midlife women: understanding the critical window and its clinical implications
Soares, C. N. (2014) · Menopause · doi:10.1097/gme.0000000000000193 · Cited by 134
Bordeleau, L., Pritchard, K. I., Loprinzi, C. L., Ennis, M., Jugovic, O., Warr, D., Haq, R., & Goodwin, P. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.9230 · Cited by 130 · cited 1×
“Choice of SSRI/SNRI vs gabapentin/pregabalin A randomized, crossover, multicenter trial that compared recommended doses of venlafaxine vs gabapentin, 300 mg three times a day (243), reported that both agents reduced hot flash scores by 66%, but two-thirds of patients preferred venlafaxine over gabapentin.”
BackgroundPAPA, M. Z., SCHNEIDERMAN, J., TUCKER, E., BASS, A., DRORI, Y., & ADAR, R. (1986) · Annals of Surgery · doi:10.1097/00000658-198612000-00016 · Cited by 126
Karim, R., Dell, R. M., Greene, D. F., Mack, W. J., Gallagher, J. C., & Hodis, H. N. (2011) · Menopause · doi:10.1097/gme.0b013e31821b01c7 · Cited by 125
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00718 · Cited by 125
Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally
Bachmann, G., Bouchard, C., Hoppe, D., Ranganath, R., Altomare, C., Vieweg, A., Graepel, J., & Helzner, E. (2009) · Menopause · doi:10.1097/gme.0b013e3181a48c4e · Cited by 124 · cited 1×
“dose vaginal estradiol tablets revealed no cases of endometrial hyperplasia or cancer as determined by endometrial biopsy (263, 266, 304).”
BackgroundPostmenopausal hormone use and cholecystectomy in a large prospective study.
Grodstein, F., Colditz, G. A., & Stampfer, M. J. (1994) · PubMed · Cited by 124
Hormone therapy and recurrence of venous thromboembolism among postmenopausal women
Olié, V., Plu-Bureau, G., Conard, J., Horellou, M.-H., Canonico, M., & Scarabin, P.-Y. (2011) · Menopause · doi:10.1097/gme.0b013e3181f9f7c3 · Cited by 123
Canonico, M., Oger, E., Conard, J., Meyer, G., Levesque, H., Trillot, N., Barrellier, M. ‐., Wahl, D. G., Emmerich, J., & Scarabin, P. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01933.x · Cited by 122
Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance
Freedman, R. R., & Roehrs, T. A. (2006) · Menopause · doi:10.1097/01.gme.0000227398.53192.bc · Cited by 122 · cited 2×
“In polysomnography studies, nocturnal hot flashes are more common during the first 4 hours of sleep, whereas subsequent rapid eye movement sleep suppresses hot flashes, arousals, and awakenings (30).”
BackgroundGlobal Consensus Statement on menopausal hormone therapy
de Villiers, T. J., Gass, M. L. S., Haines, C. J., Hall, J. E., Løbo, R. A., Pierroz, D. D., & REES, M. C. P. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.02.001 · Cited by 122 · cited 2×
“During ensuing years, a consensus arose that most healthy symptomatic women, without contraindications and closer to the time of menopause ( 10 y after menopause onset or age 60 y), were appropriate candidates for MHT for symptom relief (19, 20).”
BackgroundMANDEL, F. P., GEOLA, F. L., MELDRUM, D. R., LU, J. H. K., EGGENA, P., SAMBHI, M. P., HERSHMAN, J. M., & JUDD, H. L. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-1-133 · Cited by 122 · cited 1×
“5-mg vaginal cream, administered daily, results in systemic effects as evidenced by LH and FSH suppression (285).”
BackgroundTransvaginal Administration of Progesterone
FANCHIN, R., DEZIEGLER, D., BERGERON, C., RIGHINI, C., TORRISI, C., & FRYDMAN, R. (1997) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(97)00270-6 · Cited by 121
Smith, N. L., Blondon, M., Wiggins, K. L., Harrington, L. B., van Hylckama Vlieg, A., Floyd, J. S., Hwang, M., Bis, J. C., McKnight, B., Rice, K. M., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11074 · Cited by 121 · cited 2×
“are supported by observational studies (106, 108, 109).”
BackgroundMethodde Ziegler, D., Bulletti, C., MONSTIER, B. D., & JÄÄSKELÄINEN, A. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48550.x · Cited by 121
Hormone therapy and risk of myocardial infarction: a national register study
Lokkegaard, E., Andreasen, A. H., Jacobsen, R. K., Nielsen, L. H., Agger, C., & Lidegaard, O. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn408 · Cited by 120 · cited 2×
“Although observational studies suggest that a dermal route of ET may carry a lower risk of MI (101, 102), a meta-analysis reported no significant difference in CHD outcomes between oral and transdermal MHT (4).”
BackgroundGabapentin for the treatment of menopausal hot flashes: a randomized controlled trial
Butt, D. A., Lock, M., Lewis, J. E., Ross, S., & Moineddin, R. (2008) · Menopause · doi:10.1097/gme.0b013e3180dca175 · Cited by 119
Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality
Mikkola, T. S., Tuomikoski, P., Lyytinen, H., Korhonen, P., Hoti, F., Vattulainen, P., Gissler, M., & Ylikorkala, O. (2015) · Menopause · doi:10.1097/gme.0000000000000450 · Cited by 119
Breast Effects of Bazedoxifene-Conjugated Estrogens: A Randomized Controlled Trial
Pinkerton, J. V., Harvey, J. A., Pan, K., Thompson, J. R., Ryan, K. A., Chines, A. A., & Mirkin, S. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31828c5974 · Cited by 117 · cited 1×
“In trials up to 2 years, the rates of breast cancer (reported as adverse events, not clinical outcomes) were not sufficient to assess risk or benefit (186, 187).”
BackgroundSelf-citationThe use of hormone therapy for the maintenance of urogynecological and sexual health post WHI
Nappi, R. E., & Davis, S. R. (2012) · Climacteric · doi:10.3109/13697137.2012.657589 · Cited by 115 · cited 1×
“Other climacteric symptoms include sleep disturbance (6, 7), arthralgia (7–9), and vaginal dryness and dyspareunia (7, 10, 11).”
BackgroundSelf-citationHormone replacement therapy and reduced cognitive decline in older women: The Cache County Study
Carlson, M. C., Zandi, P. P., Plassman, B. L., Tschanz, J. T., Welsh-Bohmer, K. A., Steffens, D. C., Bastian, L. A., Mehta, K. M., & Breitner, J. C. S. (2001) · Neurology · doi:10.1212/wnl.57.12.2210 · Cited by 114
Postmenopausal Hormone Therapy
Steinauer, J. E., Waetjen, L. E., Vittinghoff, E., Subak, L. L., Hulley, S. B., Grady, D. G., Lin, F., & Brown, J. S. (2005) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000180394.08406.15 · Cited by 114 · cited 29×
“Arthralgia Joint pain or stiffness and general aches or pains were improved in women receiving EPT (38, 44, 52).”
BackgroundInfluentialHuang, A. J., Subak, L. L., Wing, R., West, D. S., Hernandez, A. L., Macer, J., & Grady, D. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.162 · Cited by 112
Efficacy of isoflavones in relieving vasomotor menopausal symptoms – A systematic review
Jacobs, A., Wegewitz, U., Sommerfeld, C., Grossklaus, R., & Lampen, A. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200800552 · Cited by 110
Treatment of urogenital atrophy with low-dose estradiol: preliminary results
Santen, R. J., Pinkerton, J. V., Conaway, M. C., Ropka, M. E., Wisniewski, L., Demers, L., & Klein, K. O. (2002) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200205000-00006 · Cited by 110
Self-citationHitchcock, C. L., & Prior, J. C. (2012) · Menopause · doi:10.1097/gme.0b013e318247f07a · Cited by 110 · cited 1×
“In RCTs, oral synthetic progestogens (Table 5) (174, 175) and micronized progesterone (176) were effective.”
Backgroundvan der Laak, J. A. W. M., de Bie, L. M. T., de Leeuw, H., de Wilde, P. C. M., & Hanselaar, A. G. J. M. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.6.446 · Cited by 109
Labrie, F., Cusan, L., Gomez, J.-L., Côté, I., Bérubé, R., Bélanger, P., Martel, C., & Labrie, C. (2009) · Menopause · doi:10.1097/gme.0b013e31817b6132 · Cited by 108
MacGregor, C. A., Canney, P. A., Patterson, G., McDonald, R., & Paul, J. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.01.005 · Cited by 107
Minimized estradiol absorption with ultra-low-dose 10 μg 17β-estradiol vaginal tablets
Eugster-Hausmann, M., Waitzinger, J., & Lehnick, D. (2010) · Climacteric · doi:10.3109/13697137.2010.483297 · Cited by 107 · cited 1×
“though not all studies demonstrate this effect (267, 275).”
BackgroundSoy food consumption and breast cancer prognosis
Caan, B. J., Natarajan, L., Parker, B., Gold, E. B., Thomson, C., Newman, V., Rock, C. L., Pu, M., Al-Delaimy, W., & Pierce, J. P. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-1041 · Cited by 106 · cited 1×
“Caution is advised because some of these agents, when consumed as supplements, can exert estrogenic effects, a concern in breast cancer survivors although dietary soy appears to have no adverse effects on breast cancer prognosis (248).”
BackgroundMoyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-1-201301010-00553 · Cited by 106
Shufelt, C. L., Merz, C. N. B., Prentice, R. L., Pettinger, M. B., Rossouw, J. E., Aroda, V. R., Kaunitz, A. M., Lakshminarayan, K., Martin, L. W., Phillips, L. S., et al. (2014) · Menopause · doi:10.1097/gme.0b013e31829a64f9 · Cited by 106 · cited 2×
“Although observational studies suggest that a dermal route of ET may carry a lower risk of MI (101, 102), a meta-analysis reported no significant difference in CHD outcomes between oral and transdermal MHT (4).”
BackgroundA randomized, controlled pilot study of acupuncture treatment for menopausal hot flashes
Avis, N. E., Legault, C., Coeytaux, R. R., Pian-Smith, M., Shifren, J. L., Chen, W., & Valaskatgis, P. (2008) · Menopause · doi:10.1097/gme.0b013e31816d5b03 · Cited by 106
Roach, R. E. J., Lijfering, W. M., Helmerhorst, F. M., Cannegieter, S. C., Rosendaal, F. R., & Vlieg, A. V. H. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12060 · Cited by 105
Ekin, M., Yaşar, L., Savan, K., Temür, M., Uhri, M., Gencer, I., & Kıvanç, E. (2010) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-010-1382-8 · Cited by 105
Bolaños, R., Del Castillo, A., & Francia, J. (2010) · Menopause · doi:10.1097/gme.0b013e3181cb4fb5 · Cited by 105
Lose, G., & Englev, E. (2000) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2000.tb10408.x · Cited by 104
Prevalence of menopausal symptoms in Asian midlife women: a systematic review
Islam, R. M., Gartoulla, P., Bell, R. J., Fradkin, P., & Davis, S. R. (2014) · Climacteric · doi:10.3109/13697137.2014.937689 · Cited by 104
Self-citationHou, N., Hong, S., Wang, W., Olopade, O. I., Dignam, J. J., & Huo, D. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt207 · Cited by 103
Fournier, A., Dossus, L., Mesrine, S., Vilier, A., Boutron-Ruault, M.-C., Clavel-Chapelon, F., & Chabbert-Buffet, N. (2014) · American Journal of Epidemiology · doi:10.1093/aje/kwu146 · Cited by 102 · cited 1×
“Micronized progesterone and dydrogesterone, in combination with estrogen, have been associated with an approximate 2-fold increase in endometrial cancer when continued beyond 5 years in a large observational study (68).”
BackgroundTorres-Santiago, L., Mericq, V., Taboada, M., Unanue, N., Klein, K. O., Singh, R., Hossain, J., Santen, R. J., Ross, J. L., & Mauras, N. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4243 · Cited by 99
Self-citationEffects of Preoperative Local Estrogen in Postmenopausal Women With Prolapse: A Randomized Trial
Rahn, D. D., Good, M. M., Roshanravan, S. M., Shi, H., Schaffer, J. I., Singh, R. J., & Word, R. A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1216 · Cited by 99 · cited 1×
“but it may be advantageous preoperatively (273).”
The effects of tibolone on mood and libido
Davis, S. R. (2002) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200205000-00004 · Cited by 98
Self-citationBazedoxifene/conjugated estrogens and quality of life in postmenopausal women
Utian, W. H., Yu, H., Bobula, J. D., Mirkin, S., Olivier, S., & Pickar, J. H. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.06.006 · Cited by 97 · cited 6×
“In RCTs, both CEE/BZA and CEE/MPA improved sleep disturbance and time to fall asleep (185).”
BackgroundInfluentialShumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000089954.22841.3b · Cited by 96
Oestrogen, glycogen and vaginal candidiasis
Dennerstein, G. J., & Ellis, D. H. (2001) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2001.tb01238.x · Cited by 95 · cited 1×
“Side effects include vulvovaginal candidiasis (289, 290) and, with higher dosing and systemic absorption, vaginal bleeding and breast pain (289).”
BackgroundSimon, J. A., Hunninghake, D. B., Agarwal, S. K., Lin, F., Cauley, J. A., Ireland, C. C., Pickar, J. H., & for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-7-200110020-00008 · Cited by 94 · cited 1×
“With EPT, the excess risk was 23 women/1000 (44), similar to another trial (119).”
BackgroundBreast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens
Harvey, J. A., Pinkerton, J. V., Baracat, E. C., Shi, H., Chines, A. A., & Mirkin, S. (2013) · Menopause · doi:10.1097/gme.0b013e318271f5e7 · Cited by 94 · cited 1×
“In trials up to 2 years, the rates of breast cancer (reported as adverse events, not clinical outcomes) were not sufficient to assess risk or benefit (186, 187).”
BackgroundSelf-citationAcupuncture for treating menopausal hot flushes: a systematic review
Lee, M. S., Shin, B., & Ernst, E. (2009) · Climacteric · doi:10.1080/13697130802566980 · Cited by 93
Moyer, V. A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00717 · Cited by 92
Liu, B., Beral, V., Balkwill, A., Green, J., Sweetland, S., Reeves, G., & Collaborators, F. T. M. W. S. (2008) · BMJ · doi:10.1136/bmj.a386 · Cited by 92 · cited 1×
“Observational studies report increased risk with oral, but not transdermal, estradiol (121, 122) and increased dose and duration (120, 123).”
BackgroundThe effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety
Stovall, D. W., Utian, W. H., Gass, M. L. S., Qu, Y., Muram, D., Wong, M., & Plouffe, L. (2007) · Menopause · doi:10.1097/gme.0b013e318031a83d · Cited by 91 · cited 1×
“In two clinical trials, vaginal, but not oral (301) ET, was safely used to treat vaginal symptoms in women taking raloxifene without untoward endometrial effects (302, 303).”
MethodPostmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women
Kang, J. H., Weuve, J., & Grodstein, F. (2004) · Neurology · doi:10.1212/01.wnl.0000132522.13574.67 · Cited by 91 · cited 1×
“Some studies of postmenopausal women treated with estradiol reported an improvement in verbal memory and executive function (135–138), whereas other studies did not associate CEE therapy with cognitive improvement (139, 140).”
ResultAcupuncture for vasomotor menopausal symptoms: a systematic review
Cho, S., & Whang, W. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181a48abd · Cited by 90
Phytoestrogens for menopausal symptoms: A review
Eden, J. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.03.006 · Cited by 90
Ineffectiveness of Sertraline for Treatment of Menopausal Hot Flushes: A Randomized Controlled Trial
Grady, D., Cohen, B., Tice, J., Kristof, M., Olyaie, A., & Sawaya, G. F. (2007) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000258278.73505.fa · Cited by 88
Severity of menopausal symptoms and use of both conventional and complementary/alternative therapies
Keenan, N. L., Mark, S., Fugh-Berman, A., Browne, D., Kaczmarczyk, J., & Hunter, C. (2003) · Menopause · doi:10.1097/01.gme.0000064865.58809.3e · Cited by 87
de Lauzon-Guillain, B., Fournier, A., Fabre, A., Simon, N., Mesrine, S., Boutron-Ruault, M.-C., Balkau, B., & Clavel-Chapelon, F. (2009) · Diabetologia · doi:10.1007/s00125-009-1456-y · Cited by 86
Nelken, R. S., Özel, B. Z., Leegant, A., Felix, J. C., & Mishell, D. R. (2011) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3182104977 · Cited by 86
Complications of pelvic organ prolapse surgery and methods of prevention
de Tayrac, R., & Sentilhes, L. (2013) · International Urogynecology Journal · doi:10.1007/s00192-013-2177-9 · Cited by 85 · cited 1×
“vaginal ET prevents or improves pelvic prolapse (272),”
BackgroundRossouw, J. E., Cushman, M., Greenland, P., Lloyd-Jones, D. M., Bray, P., Kooperberg, C., Pettinger, M., Robinson, J., Hendrix, S., & Hsia, J. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.20.2245 · Cited by 85 · cited 1×
“For a woman at intermediate risk, family history, coronary artery calcium score, C-reactive protein, and ankle-brachial index can further stratify risk (144); inflammatory markers and lipid ratios predict treatment-related CHD events (145).”
BackgroundEffects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women
Mirkin, S., Komm, B. S., Pan, K., & Chines, A. A. (2013) · Climacteric · doi:10.3109/13697137.2012.717994 · Cited by 83
Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms
Speroff, L. (2003) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(03)00764-6 · Cited by 82 · cited 1×
“ment of moderate to severe VMS and VVA due to menopause (170, 171).”
BackgroundWhy the product labeling for low-dose vaginal estrogen should be changed
Manson, J. E., Goldstein, S. R., Kagan, R., Kaunitz, A. M., LIU, J. H., Pinkerton, J. V., Rebar, R. W., Schnatz, P. F., Shifren, J. L., Stuenkel, C. A., et al. (2014) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000316 · Cited by 82
Self-citationJuraskova, I., Jarvis, S. K., Mok, K., Peate, M., Meiser, B., Cheah, B. C., Mireskandari, S., & Friedlander, M. L. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12156 · Cited by 80
The Effect of Vitamin E on Hot Flashes in Menopausal Women
Ziaei, S., Kazemnejad, A., & Zareai, M. (2007) · Gynecologic and Obstetric Investigation · doi:10.1159/000106491 · Cited by 80
Brown, J., Hess, K. L., Brown, S., Murphy, C. K., Waldman, A. L., & Hezareh, M. (2013) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31828786f8 · Cited by 80 · cited 1×
“with an increased rate of bacterial vaginosis (260).”
BackgroundLevine, M., Moutquin, J., Walton, R., & Feightner, J. (2001) · Europe PMC (PubMed Central) · Cited by 79
Jenks, B. H., Iwashita, S., Nakagawa, Y., Ragland, K., Lee, J., Carson, W. H., Ueno, T., & Uchiyama, S. (2012) · Journal of Women s Health · doi:10.1089/jwh.2011.3153 · Cited by 79
Joffe, H., Crawford, S., Economou, N., Kim, S., Regan, S., Hall, J. E., & White, D. (2013) · Sleep · doi:10.5665/sleep.3244 · Cited by 79 · cited 1×
“A recent study that induced estrogen deficiency in healthy premenopausal women with a GnRH agonist directly demonstrated that hot flashes are associated with three factors: 1) an increase in episodes of waking after sleep-onset; 2) a decrease in perceived sleep efficiency; and 3) a statistically significant correlatio…”
BackgroundSuppression of vasomotor and vulvovaginal symptoms with continuous oral 17β-estradiol
Notelovitz, M., & Mattox, J. H. (2000) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200007050-00005 · Cited by 79 · cited 1×
“However, when these and other published data are taken into account (213, 217, 236, 245), the limited evidence available suggests that standard-dose MHT is more effective than nonhormonal agents.”
BackgroundPruthi, S., Qin, R., Terstreip, S. A., Liu, H., Loprinzi, C. L., Shah, T. R. C., Tucker, K. F., Dakhil, S. R., Bury, M. J., Carolla, R. L., et al. (2012) · Menopause · doi:10.1097/gme.0b013e318223b021 · Cited by 77
Paced Respiration for Vasomotor and Other Menopausal Symptoms: A Randomized, Controlled Trial
Carpenter, J. S., Burns, D. S., Wu, J., Otte, J. L., Schneider, B. P., Ryker, K., Tallman, E. F., & Yu, M. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2202-6 · Cited by 76
Herber-Gast, G.-C. M., & Mishra, G. D. (2013) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.049965 · Cited by 76
Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial
Cohen, L. S., Joffe, H., Guthrie, K. A., Ensrud, K. E., Freeman, M., Carpenter, J. S., Learman, L. A., Newton, K. M., Reed, S. D., Manson, J. E., et al. (2014) · Menopause · doi:10.1097/gme.0b013e31829e40b8 · Cited by 76 · cited 1×
“The MSFLASH trial showed that omega-3 fatty acids do not improve VMS (246).”
BackgroundVulvovaginal Candidiasis in Postmenopausal Women: The Role of Hormone Replacement Therapy
Fischer, G., & Bradford, J. (2011) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0b013e3182241f1a · Cited by 75 · cited 1×
“Side effects include vulvovaginal candidiasis (289, 290) and, with higher dosing and systemic absorption, vaginal bleeding and breast pain (289).”
BackgroundWild, R. A., Wu, C., Curb, J. D., Martin, L. W., Phillips, L., Stefanick, M., Trevisan, M., & Manson, J. E. (2013) · Menopause · doi:10.1097/gme.0b013e31826f80e0 · Cited by 72 · cited 1×
“In a nested case-control study in the WHI, women with MetS at baseline were twice as likely to have CHD events while taking oral MHT as with placebo (147).”
BackgroundVaginal Hormone Therapy for Urogenital and Menopausal Symptoms
Ballagh, S. A. (2005) · Seminars in Reproductive Medicine · doi:10.1055/s-2005-869480 · Cited by 72 · cited 1×
“decrease, suggesting possible systemic effects (278, 279).”
Donne, M. L., Caruso, C., Mancuso, A., Costa, G., Iemmo, R., Pizzimenti, G., & Cavallari, V. (2010) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-010-1545-7 · Cited by 72
Prior, J. C., Nielsen, J. D., Hitchcock, C. L., Williams, L. A., Vigna, Y. M., & Dean, C. B. (2007) · Clinical Science · doi:10.1042/cs20060228 · Cited by 72 · cited 1×
“In RCTs, oral synthetic progestogens (Table 5) (174, 175) and micronized progesterone (176) were effective.”
BackgroundKicovic, P. M., Cortés-Prieto, J., Milojević, S., Haspels, A. A., & Aljinovic, A. (1980) · Maturitas · doi:10.1016/0378-5122(80)90029-8 · Cited by 71 · cited 1×
“Estriol is considered a low-affinity estrogen and, despite increased plasma concentration after repeated vaginal administration, is not considered to have substantial systemic effects (286, 287).”
BackgroundPaced breathing compared with usual breathing for hot flashes
Sood, R., Sood, A., Wolf, S. L., Linquist, B. M., Liu, H., Sloan, J. A., Satele, D. V., Loprinzi, C. L., & Barton, D. L. (2013) · Menopause · doi:10.1097/gme.0b013e31826934b6 · Cited by 71
Goodwin, P. J., & Stambolic, V. (2011) · The Breast · doi:10.1016/s0960-9776(11)70291-0 · Cited by 70 · cited 1×
“The insulin resistance associated with obesity also confounds the relationship between obesity and breast cancer risk (86).”
BackgroundPremenopausal vasomotor symptoms in an ethnically diverse population
Reed, S. D., Lampe, J. W., Qu, C., Copeland, W. K., Gundersen, G., Fuller, S., & Newton, K. M. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3182952228 · Cited by 70
Tom, S. E., Kuh, D., Guralnik, J. M., & Mishra, G. D. (2010) · Menopause · doi:10.1097/gme.0b013e3181dd55b0 · Cited by 70 · cited 1×
“Other climacteric symptoms include sleep disturbance (6, 7), arthralgia (7–9), and vaginal dryness and dyspareunia (7, 10, 11).”
BackgroundVerhoeven, M. O., van der Mooren, M. J., van de Weijer, P. H. M., Verdegem, P. J. E., van der Burgt, L. M. J., & Kenemans, P. (2005) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000170603.63022.62 · Cited by 68
Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience
Loprinzi, C. L., Barton, D. L., Sloan, J. A., Novotny, P. J., Dakhil, S. R., Verdirame, J. D., Knutson, W. H., Kelaghan, J. W., & Christensen, B. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181679150 · Cited by 67
Land, S. R., Wickerham, D. L., Costantino, J. P., Ritter, M. W., Vogel, V. G., Lee, M., Pajon, E. R., Wade, J. L., Dakhil, S. R., Lockhart, J. B., et al. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000238649.97517.22 · Cited by 66
Pinkerton, J. V., Shifren, J. L., Valleur, J. L., Rosen, A. S., Roesinger, M., & Siddhanti, S. R. (2003) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200310010-00008 · Cited by 66
Self-citationVaginal Estrogen Preparations: A Review of Safety and Efficacy for Vaginal Atrophy
Crandall, C. J. (2002) · Journal of Women s Health · doi:10.1089/154099902762203704 · Cited by 65
Endometrial Cancer in Postmenopausal Women Using Estradiol–Progestin Therapy
Jaakkola, S., Lyytinen, H. K., Pukkala, ., & Ylikorkala, O. (2009) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181bea950 · Cited by 65 · cited 1×
“Clinicians can administer progestogen orally, transdermally by patch, vaginally, or by intrauterine administration (172).”
BackgroundLobo, R. A., Pinkerton, J. V., Gass, M. L. S., Dorin, M. H., Ronkin, S., Pickar, J. H., & Constantine, G. (2010) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000367516.48912.6a · Cited by 64
Self-citationSimon, J. A., Portman, D. J., & Mabey, R. G. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.12.005 · Cited by 63 · cited 2×
“Two year-long studies (313, 314) demonstrated sustained vaginal benefits.”
BackgroundKim, D., Jeong, J. C., Kim, K. H., Rho, J. J., Choi, M. S., Yoon, S. H., Choi, S., Kang, K., Ahn, H. Y., & Lee, M. S. (2011) · Acupuncture in Medicine · doi:10.1136/aim.2011.004085 · Cited by 63
Saxena, T., Lee, E., Henderson, K. D., Clarke, C. A., West, D. W., Marshall, S. F., Deapen, D., Bernstein, L., & Ursin, G. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0162 · Cited by 63 · cited 1×
“Observational studies also report a greater risk when EPT is started close to menopause (79, 85, 93) and with continuous rather than with cyclic regimens (78, 82, 94).”
BackgroundSwanson, S. G., Drosman, S. R., Helmond, F. A., & Stathopoulos, V. M. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000247016.41007.c9 · Cited by 62 · cited 1×
“There is no endometrial thickening (197) or increase in myoma with tibolone (200).”
BackgroundJaakkola, S., Lyytinen, H. K., Dyba, T. A., Ylikorkala, O., & Pukkala, . (2010) · International Journal of Cancer · doi:10.1002/ijc.25762 · Cited by 62
Slater, C. C., Hodis, H. N., Mack, W. J., Shoupe, D., Paulson, R. J., & Stanczyk, F. Z. (2001) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200105000-00009 · Cited by 61
Nachtigall, L. E., Raju, U., Banerjee, S., Wan, L. S., & Levitz, M. (2000) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200007040-00006 · Cited by 60
Serum Lipid Profile Improved by Ultra-Low Doses of 17β-Estradiol in Elderly Women1
Naessen, T., Rodriguez-Macias, K., & Lithell, H. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7524 · Cited by 58
Efficacy of citalopram on climacteric symptoms
Kalay, A. E., Demir, B., Haberal, A., Kalay, M., & Kandemir, O. (2007) · Menopause · doi:10.1097/01.gme.0000243571.55699.4a · Cited by 58
Pukkala, ., Tulenheimo‐Silfvast, A., & Leminen, A. (2001) · Cancer Causes & Control · doi:10.1023/a:1008934919159 · Cited by 57 · cited 1×
“Limited information is available about the safety of long cycle intermittent use of progestogens, but concern has been raised about increased risk of endometrial cancer (72, 73).”
BackgroundRisk factors for night sweats and hot flushes in midlife: results from a prospective cohort study
Herber-Gast, G.-C. M., Mishra, G. D., van der Schouw, Y. T., Brown, W. J., & Dobson, A. J. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3182844a7c · Cited by 56
Villaseca, P. (2011) · Climacteric · doi:10.3109/13697137.2011.624214 · Cited by 56
Hammar, M., Van De Weijer, P., Franke, H., Pornel, B., Von Mauw, E., Nijland, E., & TOTAL Study Investigators Group (2007) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2007.01537.x · Cited by 55 · cited 1×
“The incidence of breast tenderness is low (around 3%), (201, 202), and neither mammographic density nor invasive breast cancer was increased; however, the risk of colon cancer was decreased (199, 201).”
BackgroundMeikle, A. W. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79192-3 · Cited by 55
Pschera, H., Hjerpe, A., & Carlström, K. (2010) · Gynecologic and Obstetric Investigation · doi:10.1159/000293657 · Cited by 55
Meason, B. (2013) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2012.12.007 · Cited by 53
Kravitz, H. M., Schott, L. L., Joffe, H., Cyranowski, J. M., & Bromberger, J. T. (2014) · Psychological Medicine · doi:10.1017/s0033291714000075 · Cited by 53
Parsons, A. K. (2003) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)02726-6 · Cited by 52 · cited 1×
“In two clinical trials, vaginal, but not oral (301) ET, was safely used to treat vaginal symptoms in women taking raloxifene without untoward endometrial effects (302, 303).”
MethodNorton, S., Chilcot, J., & Hunter, M. S. (2014) · Menopause · doi:10.1097/gme.0000000000000095 · Cited by 52
Fedele, L., Bianchi, S., Raffaelli, R., & Zanconato, G. (2000) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(99)00115-3 · Cited by 52 · cited 1×
“There is no endometrial thickening (197) or increase in myoma with tibolone (200).”
BackgroundThe menopausal experience among indigenous women of Sarawak, Malaysia
Alwi, S. A. R. S., Lee, P. Y., Awi, I., Mallik, P. S., & Haizal, M. N. M. (2009) · Climacteric · doi:10.3109/13697130902919519 · Cited by 52
Women's Perceptions About Lubricant Use and Vaginal Wetness During Sexual Activities
Jozkowski, K. N., Herbenick, D., Schick, V., Reece, M., Sanders, S. A., & Fortenberry, J. D. (2012) · The Journal of Sexual Medicine · doi:10.1111/jsm.12022 · Cited by 49 · cited 1×
“vaginal dryness and preventing dyspareunia (258).”
Endometrial safety of ultra-low-dose Vagifem 10 μg in postmenopausal women with vaginal atrophy
Ulrich, L. S. G., Naessén, T., Elia, D., Goldstein, J. A., Eugster-Hausmann, M., & on behalf of the VAG-1748 trial investigators (2010) · Climacteric · doi:10.3109/13697137.2010.481058 · Cited by 49 · cited 1×
“dose vaginal estradiol tablets revealed no cases of endometrial hyperplasia or cancer as determined by endometrial biopsy (263, 266, 304).”
BackgroundDifferential effects of menopausal therapies on the endometrium
Mirkin, S., Archer, D. F., Taylor, H. S., Pickar, J. H., & Komm, B. S. (2014) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000186 · Cited by 48 · cited 5×
“In RCTs, both CEE/BZA and CEE/MPA improved sleep disturbance and time to fall asleep (185).”
InfluentialShort and long term effects of tibolone in postmenopausal women
Formoso, G., Perrone, E., Maltoni, S., Balduzzi, S., D'Amico, R., Bassi, C., Basevi, V., Marata, A. M., Magrini, N., & Maestri, E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008536.pub2 · Cited by 48
Cicinelli, E., Naro, E. D., de Ziegler, D., Matteo, M., Morgese, S., Galantino, P., Brioschi, P.-A., & Schönauer, S. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.341 · Cited by 47
Estrogen therapy in gynecological cancer survivors
Guidozzi, F. (2013) · Climacteric · doi:10.3109/13697137.2013.806471 · Cited by 46 · cited 1×
“In the absence of RCT findings to guide practice recommendations, the decision to use ET remains controversial and involves assessing the severity of postmenopausal symptoms and tumor characteristics (296, 297).”
BackgroundSong, Y., Santen, R. J., Wang, J., & Yue, W. (2012) · Endocrinology · doi:10.1210/en.2012-1583 · Cited by 46 · cited 1×
“CEE and estradiol may also have differential effects as suggested by in vitro (87) and primate (88) studies.”
BackgroundSelf-citationChilcot, J., Norton, S., & Hunter, M. S. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.01.007 · Cited by 45
Hormonal therapies for new onset and relapsed depression during perimenopause
Worsley, R., Davis, S. R., Gavrilidis, E., Gibbs, Z., Lee, S. J., Burger, H., & Kulkarni, J. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.06.011 · Cited by 45
Self-citationEffects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women
Delmas, P. D., Davis, S. R., Hensen, J., Adámi, S., van Os, S., & Nijland, E. A. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0545-3 · Cited by 45 · cited 1×
“Tibolone prevents postmenopausal bone loss and osteoporotic fractures in women with osteoporosis (198, 199), but is not approved for this purpose because of the increased risk of stroke in older women with osteoporosis initiating therapy at ages 60 years (199).”
BackgroundSelf-citationBotsis, D. S., Kassanos, D. P., Kalogirou, D., Antoniou, G., Vitoratos, N., & Karakitsos, P. (1997) · Maturitas · doi:10.1016/s0378-5122(96)01070-5 · Cited by 44
Laakmann, E., Grajecki, D., Doege, K., zu Eulenburg, C., & Bühling, K. J. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650772 · Cited by 44
Postmenopausal Hormone Therapy and Mortality
Atkins, C. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711063371913 · Cited by 44
Fournier, A., Berrino, F., & Clavel‐Chapelon, F. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9604-x · Cited by 43
Racine, A., Bijon, A., Fournier, A., Mesrine, S., Clavel-Chapelon, F., Carbonnel, F., & Boutron-Ruault, M.-C. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121490 · Cited by 43 · cited 1×
“Observational studies report increased risk with oral, but not transdermal, estradiol (121, 122) and increased dose and duration (120, 123).”
Background&NA; (2006) · Journal of Burn Care & Research · doi:10.1097/01.gme.0000186663.36211.c0 · Cited by 42
Ross, D., Cooper, A. J., Pryse-Davies, J., Bergeron, C., Collins, W. P., & Whitehead, M. I. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70297-7 · Cited by 42
Early age of natural menopause in India, a biological marker for early preventive health programs
Singh, M. (2012) · Climacteric · doi:10.3109/13697137.2011.643514 · Cited by 42
Obiorah, I. E., & Jordan, V. C. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31828865a5 · Cited by 41
Stellate-ganglion block as a treatment for severe postmenopausal flushing
van Gastel, P., KALLEWAARD, J., van der Zanden, M., & de Boer, H. (2012) · Climacteric · doi:10.3109/13697137.2012.709889 · Cited by 41
Bardia, A., Novotny, P., Sloan, J., Barton, D., & Loprinzi, C. (2009) · Menopause · doi:10.1097/gme.0b013e31818c91ca · Cited by 40
Low-Dose Estrogen Therapy for Menopausal Women: A Review of Efficacy and Safety
Crandall, C. J. (2003) · Journal of Women s Health · doi:10.1089/154099903322447701 · Cited by 40 · cited 1×
“Cutaneous and transdermal estradiol, administered via percutaneous gels, sprays, emulsions, or transdermal patches, have a similar efficacy as oral ET in reducing climacteric symptoms and are easily tailored to the individual (164, 165).”
BackgroundCompetency in Menopause Management: Whither Goest the Internist?
Santen, R. J., Stuenkel, C. A., Burger, H., & Manson, J. E. (2014) · Journal of Women s Health · doi:10.1089/jwh.2014.4746 · Cited by 40
Self-citationMorrow, M. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70081-6 · Cited by 40
Pup, L. D., Francia, R. D., Cavaliere, C., Facchini, G., Giorda, G., Paoli, P. D., & Berretta, M. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328365288e · Cited by 39 · cited 29×
“A series of RCTs up to 2 years in duration evaluated effects of CEE/BZA (0.45 mg/20 mg, the approved dose) compared with MHT (CEE 0.45 mg/MPA 1.5 mg) (178–180).”
BackgroundInfluentialFiorilli, A., Molteni, B., & Milani, M. (2005) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2004.10.011 · Cited by 39
A health survey of Beijing middle-aged registered nurses during menopause
Liu, M., Wang, Y., Li, X., Liu, P., Yao, C., Ding, Y., Zhu, S., Bai, W., & Liu, J. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.10.006 · Cited by 38 · cited 1×
“It is less clear whether anxiety, irritability, depression, palpitations, skin dryness, loss of libido, and fatigue can be attributed to menopause (7, 9, 12).”
BackgroundNon-estrogenic approaches for the treatment of climacteric symptoms
Albertazzi, P. (2007) · Climacteric · doi:10.1080/13697130701440980 · Cited by 37
Cardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trials
Komm, B. S., Thompson, J. R., & Mirkin, S. (2014) · Climacteric · doi:10.3109/13697137.2014.992011 · Cited by 37 · cited 1×
“In trials of up to 2 years in women ages 40 to 65, rates of cardiovascular events, cancers (breast, endometrial, ovarian), and mortality were similar to placebo (191), but studies were underpowered to draw firm conclusions regarding these endpoints.”
Aguirre, W., Chedraui, P., Mendoza, J., & Ruilova, I. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903511539 · Cited by 36 · cited 1×
“Relative efficacy of nonhormonal prescription therapies vs estrogens A limited number of head-to-head RCTs have compared varying estrogen doses, preparations, and routes of administration with nonhormonal agents (213, 240, 244).”
BackgroundCurrent recommendations: what is the clinician to do?
Manson, J. E. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.02.043 · Cited by 35 · cited 3×
“Clonidine is contraindicated in patients with low blood pressure and may cause lightheadedness, hypotension, headache, and constipation; sudden cessation of treatment can be associated with significant increments in blood pressure (63).”
BackgroundMethodFerenczy, A. S., Gelfand, M. M., van de Weijer, P. H. M., & Rioux, J. E. (2002) · Climacteric · doi:10.1080/713605196 · Cited by 35
Prevalence of menopausal symptoms in Australian women at midlife: a systematic review
Gartoulla, P., Islam, R. M., Bell, R. J., & Davis, S. R. (2013) · Climacteric · doi:10.3109/13697137.2013.865721 · Cited by 35
Self-citationThe variable response of women with menopausal hot flashes when treated with sertraline
Kerwin, J. P., Gordon, P., & Senf, J. H. (2007) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31802e7f22 · Cited by 32
Effective and clinically meaningful non-hormonal hot flash therapies
Guttuso, T. J. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.01.023 · Cited by 32
Al‐Azzawi, F., & Buckler, H. M. (2003) · Climacteric · doi:10.1080/cmt.6.2.118.127 · Cited by 32 · cited 1×
“ment of moderate to severe VMS and VVA due to menopause (170, 171).”
BackgroundWoods, N. F., & Mitchell, E. S. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.10.008 · Cited by 32
Caswell, M., & Kane, M. H. (2002) · PubMed · Cited by 31
Sun, Z., Hao, Y., & Zhang, M. (2013) · Gynecologic and Obstetric Investigation · doi:10.1159/000348564 · Cited by 30
Efficacy and Tolerability of a Novel Estradiol Vaginal Ring for Relief of Menopausal Symptoms
Speroff, L. (2003) · Obstetrics and Gynecology · doi:10.1097/00006250-200310000-00026 · Cited by 30
Kreatsoulas, C., & Anand, S. S. (2013) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1625 · Cited by 29
Kariuki, J. K., Stuart‐Shor, E., Leveille, S. G., & Hayman, L. L. (2013) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-13-123 · Cited by 29 · cited 1×
“Country- and population-specific CVD risk calculators are available to quantify individual risk per local guidelines (143).”
BackgroundWildemeersch, D. A., Pylyser, K., Wever, N. D., Pauwels, P., & Tjalma, W. A. A. (2007) · Maturitas · doi:10.1016/j.maturitas.2006.11.010 · Cited by 29
Hart, A. R., Luben, R., Welch, A. A., Bingham, S. A., & Khaw, K. (2008) · Digestion · doi:10.1159/000113897 · Cited by 28
Haskell, S. G., Bean‐Mayberry, B., & Gordon, K. S. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31818fbff5 · Cited by 28
Jondet, M., Maroni, M., Yaneva, H., Brin, S., Peltier‐Pujol, F., & Pelissier, C. (2002) · Maturitas · doi:10.1016/s0378-5122(01)00260-2 · Cited by 27 · cited 1×
“In contrast, one RCT comparing micronized progesterone with MPA (3 y) (69), a second RCT comparing micronized progesterone with chlormadinone acetate (18 mo) (70), and a third trial of single-tablet formulation of cyclical estradiol-dydrogesterone (2 y) (71) each demonstrated endometrial safety.”
BackgroundDorr, M. B., Nelson, A. L., Mayer, P. R., Ranganath, R., Norris, P. M., Helzner, E. C., & Preston, R. A. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.03.076 · Cited by 27 · cited 1×
“ET), systemic absorption may decrease (276, 277).”
Low levels of endogenous estradiol protect bone mineral density in young postmenopausal women
Bagur, A., Oliveri, B., Mautalén, C., Belotti, M., Mastaglia, S. R., Yankelevich, D., Sayegh, F., & Royer, M. R. (2004) · Climacteric · doi:10.1080/13697130410001713788 · Cited by 26
Santen, R. J. (1998) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199810001-00001 · Cited by 26 · cited 1×
“An accepted philosophy is that a fully informed patient should be empowered to make a decision that best balances individual QOL benefits against potential health risks (21).”
BackgroundSelf-citationvan Haaften, M., Donker, G. H., Haspels, A. A., & Thijssen, J. H. H. (1989) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(89)90055-1 · Cited by 25
Stearns, V., Beebe, K. L., Iyengar, M. K., & Dube, E. (2003) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000102584.13943.dd · Cited by 25
Morelli, M., Cello, A. D., Venturella, R., Mocciaro, R., D’Alessandro, P., & Zullo, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.730579 · Cited by 24
Tice, J. A., Ettinger, B., Ensrud, K. E., Wallace, R. B., Blackwell, T., & Cummings, S. R. (2003) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000093672.76878.03 · Cited by 24
Tiefert, M. A., Roy, H., & Moudrianakis, E. N. (1977) · Biochemistry · doi:10.1021/bi00630a014 · Cited by 23 · cited 1×
“This agent (193) is available in many countries outside of the United States at doses of 1.”
BackgroundIs there evidence for preferential delivery of ovarian estradiol to the endometrium?
Tourgeman, D. E., Boostanfar, R., Chang, L., Lu, J., Stanczyk, F. Z., & Paulson, R. J. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(01)01786-1 · Cited by 21
Sharifi, M., & Lewiecki, E. M. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.893819 · Cited by 20
Non hormonal interventions for hot flushes in women with a history of breast cancer
Gabriel Rada, G., Daniel Capurro, N., Tomás Pantoja, C., Corbalán, J., Moreno, G., Luz María Letelier, S., & Vera, C. M. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004923 · Cited by 20
Predictors of placebo response in a randomized, controlled trial of phytotherapy in menopause
van Die, M. D., Teede, H. J., Bone, K. M., Reece, J., & Burger, H. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318199d5e6 · Cited by 19
How best is to discontinue postmenopausal hormone therapy: Immediate or tapered?
Aslan, E., Bağış, T., Kılıçdağ, E. B., Tarım, E., Erkanlı, S., & Kuşçu, E. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.06.006 · Cited by 19
Davis, S. R., Goldstat, R., Newman, A., Berry, K. L., Burger, H., Meredith, I. T., & Koch, K. (2002) · Climacteric · doi:10.1080/713605313 · Cited by 19
Self-citationDavis, S. R., Goldstat, R., Newman, A., Berry, K. L., Burger, H., Meredith, I. T., & Koch, K. (2002) · Climacteric · doi:10.1080/cmt.5.4.341.350 · Cited by 19
Self-citationHormone therapy and risk of cardiovascular outcomes and mortality in women treated with statins
Berglind, I. A., Andersen, M. T., Citarella, A., Linder, M., Sundström, A., & Kieler, H. (2014) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000345 · Cited by 18
Abraham, L., Pinkerton, J. V., Messig, M., Ryan, K. A., Komm, B. S., & Mirkin, S. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.04.008 · Cited by 18 · cited 2×
“In RCTs, both CEE/BZA and CEE/MPA improved sleep disturbance and time to fall asleep (185).”
BackgroundSelf-citationA Decade after the Women's Health Initiative—The Experts Do Agree
Stuenkel, C. A., Gass, M. L. S., Manson, J. E., Løbo, R. A., Pal, L., Rebar, R. W., & Hall, J. E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2403 · Cited by 18 · cited 2×
“During ensuing years, a consensus arose that most healthy symptomatic women, without contraindications and closer to the time of menopause ( 10 y after menopause onset or age 60 y), were appropriate candidates for MHT for symptom relief (19, 20).”
BackgroundSelf-citationVassilopoulou‐Sellin, R. (2007) · Breast Diseases A Year Book Quarterly · doi:10.1016/s1043-321x(07)80201-3 · Cited by 17
Wood, C. E., Clarkson, T. B., Chen, H., Veenstra, T. D., Xu, X., Scott, L., & Cline, J. M. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318168f0ad · Cited by 16 · cited 1×
“CEE and estradiol may also have differential effects as suggested by in vitro (87) and primate (88) studies.”
Background&NA; (2000) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200011000-00012 · Cited by 16
Grodstein, F., Manson, J. E., Stampfer, M. J., & Rexrode, K. M. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000320470.46864.a3 · Cited by 14
Vassilopoulou‐Sellin, R. (2006) · Breast Diseases A Year Book Quarterly · doi:10.1016/s1043-321x(06)80410-8 · Cited by 14
Lyytinen, H. K., Dyba, T. A., Pukkala, ., & Ylikorkala, O. (2009) · International Journal of Cancer · doi:10.1002/ijc.24996 · Cited by 13 · cited 1×
“Studies have reported similar findings with most other estrogen/progestogen combinations (38, 89, 92).”
ResultRunnebaum, B., & Rabe, T. (1999) · Reproduktionsmedizin · doi:10.1007/s004440050124 · Cited by 13
Day, S., & Bevers, T. B. (2013) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2013.10.042 · Cited by 13
Menopause: an important milestone in women’s health
Ang, S. B., & How, C. H. (2013) · Singapore Medical Journal · doi:10.11622/smedj.2013025 · Cited by 13
Efficacy and Safety of Isopropanolic Black Cohosh Extract for Climacteric Symptoms
Osmers, R. G. W., & Schnitker, J. (2005) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000186253.14228.d2 · Cited by 11
Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus
(2006) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000209495.80866.96 · Cited by 11
Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women: A Randomized Controlled Trial
Dungan, J. S. (2011) · Yearbook of Obstetrics Gynecology and Women s Health · doi:10.1016/j.yobg.2011.06.061 · Cited by 10
Suffoletto, J.-A., & Hess, R. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181a057db · Cited by 9
(2007) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000244714.80902.c6 · Cited by 9
Gompel, A., & Burger, H. (2015) · Climacteric · doi:10.3109/13697137.2015.1023615 · Cited by 8
Self-citationManson, J. E., Rimm, E. B., Colditz, G. A., Willett, W. C., Nathan, D. M., Arky, R., ROSNER, B. A., Hennekens, C. H., Speizer, F. E., & Stampfer, M. J. (1993) · Maturitas · doi:10.1016/0378-5122(93)90097-2 · Cited by 8
Hot flushes and the menopause: How long should they be expected to last?
Freeman, E. W. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.04.010 · Cited by 8
Mastaglia, S. R., Bagur, A., Royer, M., Yankelevich, D., Sayegh, F., & Oliveri, B. (2008) · Climacteric · doi:10.1080/13697130802461208 · Cited by 8
Cited by
El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., Allison, M. A., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000912 · Cited by 1,219
Gravholt, C. H., Andersen, N. H., Conway, G. S., Dekkers, O. M., Geffner, M. E., Klein, K. O., Lin, A. E., Mauras, N., Quigley, C. A., Rubin, K., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0430 · Cited by 1,101
Cardiovascular Disease in Women: Clinical Perspectives
Garcia, M., Mulvagh, S. L., Bairey Merz, C. N., Buring, J. E., & Manson, J. E. (2016) · Circulation Research · doi:10.1161/circresaha.116.307547 · Cited by 1,080
“The microvasculature in women may play an important role in the predisposition of women with autoimmune diseases to develop accelerated CVD.80 The female to male ratio for rheumatoid arthritis is 2.5:1 and for systemic lupus erythematosus is 9:1.”
InfluentialThe 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
“The reason that hormone therapy was not shown to reduce hip fracture in the subset of women aged 50 to 59 years in the WHI may be partly because of the lower baseline absolute risk of fracture in women aged between 50 and 59 years who did not have established osteoporosis.(9,168)”
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Self-citation
Metadata
- Authors
- Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-11
- Volume
- 100
- Issue
- 11
- Pages
- 3975-4011
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2162957019
- Cited by
- 884
- References
- 414
- Citations by year
- 2026: 79 · 2025: 96 · 2024: 66 · 2023: 69 · 2022: 82 · 2021: 96 · 2020: 121 · 2019: 89 · 2018: 75 · 2017: 57 · 2016: 47 · 2015: 4
- FWCI
- 52.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- menopause, hormone replacement therapy, vasomotor symptoms, climacteric, postmenopausal women, cardiovascular risk screening, breast cancer risk, ospemifene, vaginal estrogen, genitourinary syndrome of menopause, vaginal moisturizers, lifestyle intervention, personalized treatment
- MeSH terms
- Contraindications, Age Factors, Breast Neoplasms, Cardiovascular Diseases, Female, Humans, Menopause, Terminology as Topic, Risk Factors, Severity of Illness Index, Estrogen Replacement Therapy, Evidence-Based Medicine, Hot Flashes, Female Urogenital Diseases, Venous Thromboembolism, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.